Khiron Life Sciences Corp. (V:KHRN)
Business Focus: Alternative Medicine
| Sector: Healthcare | Industry: Pharmaceuticals |
| See Regulatory Filings on SEDAR | |
| Company Contact | |
| Address: | 100 King St.W. Suite 1600, 1 First Canadian Place TORONTO ON M5X 1G5 |
| Tel: | 1-833-2758984 |
| Website: | www.khiron.ca |
| IR: | See website |
| Key People | ||
| Chris Naprawa Chairman of the Board | Alvaro Torres Chief Executive Officer, Director | Helen Bellwood Interim Chief Financial Officer |
| Franziska Katterbach President, Khiron Europe | Juan Diego Alvarez Vice President, Regulatory Affairs | Manuel Buendia Vice President, Operations | Rodrigo Duran Vice President, Pharma |
| Business Overview |
| Khiron Life Sciences Corp. (Khiron) is a vertically integrated international medical cannabis company with core operations in Latin America and Europe. The Company's product lines include medical cannabis products, health services and wellbeing products. The medical cannabis product sells branded medical cannabis products. The health service operates its own network of medium complexity health centers (operating under the ILANS and Zerenia brands) and Zerenia satellite clinics offering a range of health, medical and surgical services in alignment with insurance company partners. Its wellbeing product is focused on delivering the benefits of cannabidiol (CBD) a range of various branded consumer packaged goods, such as its Kuida cosmetics line. The Company provides patient-oriented approach, physician education programs, scientific expertise, product innovation, and agricultural infrastructure. The Company sells its products in Colombia, Peru, Germany, United Kingdom and Brazil. |
| Financial Overview |
| For the nine months ended 30 September 2022, Khiron Life Sciences Corp revenues increased 36% to C$12.5M. Net loss decreased 18% to C$11.2M. Revenues reflect Medical cannabis increase from C$2.6M to C$6.9M. Lower net loss reflects Corporate governance decrease of 75% to C$651K (expense), Share-based compensation decrease of 62% to C$975K (expense), Office and general decrease of 33% to C$1.5M (expense). |
| Employees: | 310 as of Dec 31, 2021 |
| Reporting Currency: | Canadian Dollars |
| Enterprise value: | $5.33M as of Sep 30, 2022 |
| Annual revenue (TTM): | $16.14M as of Sep 30, 2022 |
| EBITDA (TTM): | -$16.86M as of Sep 30, 2022 |
| Net annual income (TTM): | -$30.66M as of Sep 30, 2022 |
| Free cash flow (TTM): | -$17.82M as of Sep 30, 2022 |
| Net Debt Last Fiscal Year: | $0.63M as of Sep 30, 2022 |
| Shares outstanding: | 218,609,396 as of Feb 3, 2023 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
US Quotes Data provided by IEX. Additional price data powered by Twelve Data. Company fundamental sourced from © Refinitiv. Click for restrictions. © Refinitiv. All rights reserved. Republication or redistribution of Refinitiv, including by framing or similar means, is prohibited without the prior written consent of Refinitiv. Refinitiv is not liable for any errors or delays in Refinitiv content, or for any actions taken in reliance on such content.
Interactive technical study charts by TradingView. Copyright © 2023 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.